PDCD1 and neoplasm: In this trial, the adjunctive anti-tumor potential of BMS-813160, used in combination with either chemotherapeutic agents or nivolumab (PD-1-targeted), is being evaluated in patients with advanced colorectal or pancreatic cancer (NTC03184870) [142].